Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network.
Bianchi S, Mosca A, Dalla Volta A, Prati V, Ortega C, Buttigliero C, Fea E, Vanella P, Valcamonico F, Zamparini M, Sirotova Z, Chiappino I, Dal Canton O, Masini C, Sacco C, Amoroso D, Montagnani F, Comandone A, Bellissimo AR, Ciccone G, Baier S, Gennari A, Tucci M, Berruti A.
Bianchi S, et al. Among authors: berruti a.
Eur J Cancer. 2021 Sep;155:127-135. doi: 10.1016/j.ejca.2021.06.034. Epub 2021 Aug 6.
Eur J Cancer. 2021.
PMID: 34371442
Clinical Trial.